Clorazepate
| Clinical data | |
|---|---|
| Trade names | Tranxene, Tranxilium, Novo-Clopate | 
| Other names | Clorazepate dipotassium | 
| AHFS/Drugs.com | Monograph | 
| MedlinePlus | a682052 | 
| Routes of administration | Oral | 
| ATC code | |
| Legal status | |
| Legal status | 
 | 
| Pharmacokinetic data | |
| Bioavailability | 91% | 
| Metabolism | Hepatic | 
| Elimination half-life | 48 hours | 
| Excretion | Renal | 
| Identifiers | |
| 
 | |
| CAS Number | 
 | 
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.041.737 | 
| Chemical and physical data | |
| Formula | C16H11ClN2O3 | 
| Molar mass | 314.73 g·mol−1 | 
| 3D model (JSmol) | |
| 
 | |
| 
 | |
| (what is this?) (verify) | |
Clorazepate, sold under the brand name Tranxene among others, is a benzodiazepine medication. It possesses anxiolytic, anticonvulsant, sedative, hypnotic, and skeletal muscle relaxant properties. Clorazepate is an unusually long-lasting benzodiazepine and serves as a prodrug for the equally long-lasting desmethyldiazepam, which is rapidly produced as an active metabolite. Desmethyldiazepam is responsible for most of the therapeutic effects of clorazepate.
It was patented in 1965 and approved for medical use in 1967.